BioMed Realty Earns Positive Outlook On Its Investment Grade Corporate Credit Rating From Moody's PR Newswire SAN DIEGO, March 31, 2014 SAN DIEGO, March 31, 2014 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its rating outlook on its investment grade corporate credit rating from Moody's Investors Service has been revised to positive from stable. The company previously received a positive outlook on its investment grade corporate credit rating from Standard & Poor's Rating Services in June 2013. According to Greg N. Lubushkin, Chief Financial Officer of BioMed Realty, "We are very pleased with the positive outlook from Moody's which reflects the sustained, systematic enhancement of our credit quality since we became the first life science real estate investment trust to receive an investment grade corporate credit rating in 2010. In addition, the recent Moody's and S&P actions validate our steady approach to growing our industry-leading portfolio, as well as our proven track record of executing a sound, long-term capital strategy which enables us to better serve the life science communities in the United States and United Kingdom." About BioMed Realty Trust BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 16.3 million rentable square feet. Additional information is available at www.biomedrealty.com. Follow us on Twitter @biomedrealty. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with tax credits, grants and other subsidies to fund development activities; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. SOURCE BioMed Realty Trust, Inc. Website: http://www.biomedrealty.com Contact: Jim Cullinan, Vice President, Marketing, (858) 207-2072, email@example.com
BioMed Realty Earns Positive Outlook On Its Investment Grade Corporate Credit Rating From Moody's
Press spacebar to pause and continue. Press esc to stop.